These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 27956228)

  • 41. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
    Rudalska R; Dauch D; Longerich T; McJunkin K; Wuestefeld T; Kang TW; Hohmeyer A; Pesic M; Leibold J; von Thun A; Schirmacher P; Zuber J; Weiss KH; Powers S; Malek NP; Eilers M; Sipos B; Lowe SW; Geffers R; Laufer S; Zender L
    Nat Med; 2014 Oct; 20(10):1138-46. PubMed ID: 25216638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K-ras mutation: analysis in a novel orthotopic inoculation model.
    Horiuchi H; Kawamata H; Fujimori T; Kuroda Y
    Int J Oncol; 2003 Oct; 23(4):957-63. PubMed ID: 12963974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.
    Kiessling MK; Schuierer S; Stertz S; Beibel M; Bergling S; Knehr J; Carbone W; de Vallière C; Tchinda J; Bouwmeester T; Seuwen K; Rogler G; Roma G
    BMC Genomics; 2016 Sep; 17(1):723. PubMed ID: 27613601
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
    Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
    Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
    [No Abstract]   [Full Text] [Related]  

  • 46. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Chen Y; Liu YC; Sung YC; Ramjiawan RR; Lin TT; Chang CC; Jeng KS; Chang CF; Liu CH; Gao DY; Hsu FF; Duyverman AM; Kitahara S; Huang P; Dima S; Popescu I; Flaherty KT; Zhu AX; Bardeesy N; Jain RK; Benes CH; Duda DG
    Sci Rep; 2017 Mar; 7():44123. PubMed ID: 28276530
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
    Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MYC-regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer.
    Hunecke D; Spanel R; Länger F; Nam SW; Borlak J
    J Pathol; 2012 Dec; 228(4):520-33. PubMed ID: 22653869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
    Lu L; Sun HC; Zhang W; Chai ZT; Zhu XD; Kong LQ; Wang WQ; Zhang KZ; Zhang YY; Zhang QB; Ao JY; Li JQ; Wang L; Wu WZ; Tang ZY
    PLoS One; 2013; 8(5):e65023. PubMed ID: 23741443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
    Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Galuppo R; Maynard E; Shah M; Daily MF; Chen C; Spear BT; Gedaly R
    Anticancer Res; 2014 Apr; 34(4):1709-13. PubMed ID: 24692700
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice.
    Li J; Piao YF; Jiang Z; Chen L; Sun HB
    World J Gastroenterol; 2009 Jun; 15(21):2602-8. PubMed ID: 19496189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
    Qiu YQ; Zhou J; Kang XS; Ding LM; Yu W; Tan FL; Deng DF
    Sci Rep; 2014 Mar; 4():4324. PubMed ID: 24632756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
    Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
    Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.